Latest Composites News

D3 Energy has overcome a brief weather-induced pause at its Nooitgedacht helium project in South Africa, with drilling operations set to restart and production testing planned shortly.

Dimerix has secured full sponsorship of the US Investigational New Drug application for its Phase 2-ready kidney drug DMX-652, setting the stage for a clinical trial targeting acute kidney injury in late 2026.

Audinate Group Limited reported a 15% revenue increase driven by its expanding Dante ecosystem and Iris acquisition, but underlying EBITDA losses widened amid restructuring and investment costs.

Marlin Global delivered a robust 3.1% gross portfolio return in July 2026, significantly outpacing its benchmark which fell 3.6%, thanks to strategic semiconductor underweighting and strong gains in tech giants Microsoft, Dexcom, and Amazon.

Papyrus Australia has arranged a further $500,000 in unsecured loan facilities from four sophisticated investors, with conversion to unsecured convertible notes subject to shareholder approval at the 2026 AGM.

ECP Emerging Growth Limited reported a sharp 20.4% portfolio decline in FY2026 amid sector-wide challenges, yet declared a fully franked final dividend of 3.15 cents per share, supported by realised gains and reserves.

MFF Capital reported a sharp 63% fall in net profit for FY26 but declared a higher fully franked dividend, underpinned by a disciplined long-term investment approach and leadership changes.

WIN Metals has validated exceptional metallurgical recoveries exceeding 95% at its Radio Gold Project, reinforcing its path toward a near-term development decision.

360 Capital REIT (ASX:TOT) reported a 382% surge in statutory profit to $6.3 million for FY26, driven by full occupancy and a strategic $10 million structured equity investment. The Fund upgraded FY27 earnings per security to 3.8 cents and forecast a 20% distribution increase.

Alterity Therapeutics has won a new US composition of matter patent for its lead drug ATH434, extending intellectual property protection to at least 2045 and boosting its commercial potential ahead of Phase 3 trials in Multiple System Atrophy.

Growthpoint Properties Australia is set to sell its Perth Woolworths distribution centre for $267.7 million, marking a significant milestone in its capital recycling strategy and expected to reduce gearing by 4%.

Anteris Technologies posted a $51.7 million loss in H1 2026 amid ramped-up R&D and clinical trial activity, supported by a $320 million capital raise and Medicare reimbursement for its DurAVR heart valve trial.